Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasinezumab in Early-Stage Parkinson's Disease
NCT07174310Phase 3Recruiting
- Sponsor
- Roche
- Start
- Nov 2025
- Primary completion
- Jun 2029
- Modality
- Monoclonal Antibodies
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing Prasinezumab with Placebo (2 arms). Primary endpoint: Time to Confirmed Motor Progression Event on Movement Disorder Society - Unified Parkinson's Disease Rating Scale Part III Score at 104 weeks. Started Nov 2025; status: recruiting.
02
Drugs
prasinezumab
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT07174310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07174310.